The partnership provides a non-dilutive path to first-in-human data for TPST-4003, but the stock remains a binary event-driven play on clinical data. Monitor for Q4 2026 dosing start and initial safety/PD data expected in H1 2027. The EPS miss is irrelevant for valuation; focus on pipeline execution and cash runway.
Price Chart
Executive Summary
Tempest Therapeutics announced a strategic partnership with Hebei Senlang Biotechnology to develop TPST-4003, an in vivo CAR-T candidate for autoimmune diseases. An investigator-initiated trial in ~10 patients with myasthenia gravis or multiple sclerosis is planned, with first dosing expected in Q4 2026. The filing is a press release with no reported financial results, and the EPS miss of -743.3% vs consensus is a mechanical artifact of a pre-revenue clinical-stage biotech, not a business deterioration signal.
Key Financial Metrics
Key Facts
- Tempest and Senlang will collaborate on TPST-4003, a CD7-targeted mRNA/LNP in vivo CAR-T candidate targeting CD19/BCMA.
- An investigator-initiated trial in ~10 patients with myasthenia gravis or multiple sclerosis is planned, with first dosing expected in Q4 2026.
- Senlang receives an exclusive option to negotiate a license for TPST-4003 in China.
- Reported EPS of -$2.53 vs consensus -$0.30, a -743.3% miss, but this is a pre-revenue clinical-stage biotech with minuscule absolute EPS.
- Revenue was $0, consistent with a pre-revenue clinical-stage company.
Financial Impact
No financial terms disclosed; partnership is early-stage with no upfront or milestone payments mentioned.
Risk Factors
- Pre-revenue clinical-stage biotech with high cash burn and going-concern risk.
- TPST-4003 is preclinical; clinical failure or delays could wipe out value.
- Partnership with Senlang is early-stage and non-binding for license; may not materialize.
- Regulatory and manufacturing risks for novel in vivo CAR-T approach.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5102 | awaiting T+20 | — | $0.5110 (−0.16%) |
Oct 20, 2026 7d ago | DEFA14A | $0.5282 | awaiting T+20 | — | $0.5110 (−3.26%) |
Oct 20, 2026 7d ago | 8-K | $0.5282 | awaiting T+20 | — | $0.5110 (−3.26%) |
Oct 19, 2026 8d ago | 8-K | $0.5762 | awaiting T+20 | — | $0.5110 (−11.32%) |
Oct 2, 2026 25d ago | EFFECT | $0.8112 | awaiting T+20 | — | $0.5110 (+37.01%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5110 (+38.55%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5110 (−47.21%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5110 (+37.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers